Therapeutic targeting of Lyn kinase to treat chorea-acanthocytosis.
| Title: | Therapeutic targeting of Lyn kinase to treat chorea-acanthocytosis. |
|---|---|
| Authors: | Peikert K; Federti E; Matte A; Constantin G; Pietronigro EC; Fabene PF; Defilippi P; Turco E; Del Gallo F; Pucci P; Amoresano A; Illiano A; Cozzolino F; Monti M; Garello F; Terreno E; Alper SL; Glaß H; Pelzl L; Akgün K; Ziemssen T; Ordemann R; Lang F; Brunati AM; Tibaldi E; Andolfo I; Iolascon A; Bertini G; Buffelli M; Zancanaro C; Lorenzetto E; Siciliano A; Bonifacio M; Danek A; Walker RH; Hermann A; De Franceschi L. |
| Contributors: | Peikert K, Federti E, Matte A, Constantin G, Pietronigro EC, Fabene PF, Defilippi P, Turco E, Del Gallo F, Pucci P, Amoresano A, Illiano A, Cozzolino F, Monti M, Garello F, Terreno E, Alper SL, Glaß H, Pelzl L, Akgün K, Ziemssen T, Ordemann R, Lang F, Brunati AM, Tibaldi E, Andolfo I, Iolascon A, Bertini G, Buffelli M, Zancanaro C, Lorenzetto E, Siciliano A, Bonifacio M, Danek A, Walker RH, Hermann A, De Franceschi L. |
| Publication Year: | 2021 |
| Collection: | Università degli studi di Torino: AperTo (Archivio Istituzionale ad Accesso Aperto) |
| Subject Terms: | Chorein; Lyn; Cell signaling; Basal ganglia; Neurodegeneration |
| Description: | Chorea-Acanthocytosis (ChAc) is a devastating, little understood, and currently untreatable neurodegenerative disease caused by VPS13A mutations. Based on our recent demonstration that accumulation of activated Lyn tyrosine kinase is a key pathophysiological event in human ChAc cells, we took advantage of Vps13a−/− mice, which phenocopied human ChAc. Using proteomic approach, we found accumulation of active Lyn, γ-synuclein and phospho-tau proteins in Vps13a−/− basal ganglia secondary to impaired autophagy leading to neuroinflammation. Mice double knockout Vps13a−/− Lyn−/− showed normalization of red cell morphology and improvement of autophagy in basal ganglia. We then in vivo tested pharmacologic inhibitors of Lyn: dasatinib and nilotinib. Dasatinib failed to cross the mouse brain blood barrier (BBB), but the more specific Lyn kinase inhibitor nilotinib, crosses the BBB. Nilotinib ameliorates both Vps13a−/− hematological and neurological phenotypes, improving autophagy and preventing neuroinflammation. Our data support the proposal to repurpose nilotinib as new therapeutic option for ChAc patients. |
| Document Type: | article in journal/newspaper |
| Language: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/33941276; info:eu-repo/semantics/altIdentifier/wos/WOS:000654817600002; volume:9; firstpage:81; lastpage:96; numberofpages:16; journal:ACTA NEUROPATHOLOGICA COMMUNICATIONS; info:eu-repo/grantAgreement/EC/H2020/European Research Council (ERC) Advanced Grant Immunoalzheimer #695714 (to GC) and FUR-UNIVR (LDF); http://hdl.handle.net/2318/1791286; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85105087773; https://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-021-01181-y |
| DOI: | 10.1186/s40478-021-01181-y |
| Availability: | http://hdl.handle.net/2318/1791286; https://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-021-01181-y |
| Rights: | info:eu-repo/semantics/openAccess |
| Accession Number: | edsbas.231B26D |
| Database: | BASE |